Cyclosporin A hepatotoxicity in 66 renal allograft recipients
- PMID: 7041349
- PMCID: PMC2962575
- DOI: 10.1097/00007890-198112000-00007
Cyclosporin A hepatotoxicity in 66 renal allograft recipients
Abstract
Liver functional abnormalities were seen in 13 (19.7%) of 66 recipients of cadaveric renal homografts treated with cyclosporin A and prednisone. However, such presumed hepatotoxicity was a minor problem in the use of cyclosporin A. The complication was less frequent than that of nephrotoxicity, was as easily manageable with reductions in the cyclosporin A dosage, and generally did not cause clinical illness. In an occasional case, late hepatotoxicity can force a therapeutic change from cyclosporin A to azathioprine, but careful consideration should be given to the dangers of subsequent rejection.
References
-
- Dreyfus M, Haerri E, Hoffman H, Kobel H. Cyclosporin A and C. New metabolites from Trichoderma Polysporum. Eur J Appl Microbiol. 1976;3:125.
-
- Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976;6:468. - PubMed
-
- Calne RY, White DJG, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 1978;2:1323. - PubMed
-
- Powles RL, Barrett AJ, Clink H, Kay HEM, Sloane J, McElwain TJ. Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet. 1978;2:1327. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical